PARIS (Reuters) – French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen’s portfolio of products treating rare diseases.

Ipsen’s shares dipped 0.6 percent after the company said the takeover would initially weigh on margins due to the costs of forthcoming trials for Clementia products, but it hoped they would recover later on.

Ipsen said it

Read More At Article Source | Article Attribution